10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In the first-line kidney cancer setting, Germany’s Merck KGaA has thrown its hat firmly into the ring, with strong data from the JAVELIN Renal 101 trial showing the firm is ready to go toe to toe with its American namesake, and others. 22 October 2018
The International AIDS Vaccine Initiative (IAVI) and Serum Institute of India, the world's largest vaccine manufacturer, today announced a strategic partnership to develop and manufacture affordable and accessible monoclonal antibody products for HIV and other global health challenges. 22 October 2018
For the first time, an immuno-oncology therapy has been shown to be effective against breast cancer, new data highlighted at the annual ESMO congress have shown. 22 October 2018
Entyvio (vedolizumab), Takeda’s gut-selective biologic that is approved as an intravenous (IV) formulation for ulcerative colitis (UC) and Crohn’s disease (CD), could soon become available in subcutaneous (SC) form. 22 October 2018
The US Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. 20 October 2018
Shares of US drugmaker Merrimack Pharmaceuticals were down 30.23% at $3.60 in pre-market trading today, after it announced the termination of the SHERLOC study. 19 October 2018
A new analysis of Lutathera (lutetium Lu 177 dotatate) NETTER-1 data has been presented at the 2018 European Society for Medical Oncology (ESMO) congress, which kicked off in Munich, Germany today, which examines the impact of Lutathera treatment on patients with low, medium or high liver tumor burden. 19 October 2018
The Parker Institute for Cancer Immunotherapy and Xyphos Biosciences today announced a collaboration to create universal CAR-T therapies to treat multiple cancer types using the company's 'convertibleCAR' platform. 18 October 2018
There was good news for two US majors with novel CGRP inhibitor migraine prevention drugs, but disappointment for another firm, when US pharmacy benefits manager (PBM) Express Scripts yesterday announced its new SafeGuardRx Migraine Care Value program, which will begin April 1, 2019. 18 October 2018
Japan’s Sosei has announced that it will not take up an option to acquire more equity in MiNA Therapeutics, the British RNA activation therapeutics company. 18 October 2018
Gilead Sciences is to collaborate with Spain's AELIX Therapeutics, a spin-off of the HIVACAT vaccine research consortium, on the development of investigational products aimed at curing HIV infection. 18 October 2018
Sweden’s Medivir says it will reduce activities “not critical to its development pipeline of drug candidates,” including cutting around 60 staff, as part of a cost-cutting plan. 17 October 2018
The US Food and Drug Administration approved Talzenna (talazoparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2 negative locally advanced or metastatic breast cancer. 17 October 2018
Intrathecal catheterization is a highly effective delivery method for drugs targeting neurological diseases, writes Brad Gien, head of surgery, North America, Envigo, in an Expert View piece. 17 October 2018
US Food and Drug Administration Commissioner Scott Gottlieb has issued a statement outlining the steps his agency is taking to modernize programs and “advance opportunities for developing more targeted therapies.” 16 October 2018
Chinese biotech Innovent Biologics wants to raise $422 million in an initial public offering (IPO) to take forward its monoclonal antibodies and other biologics in oncology, ophthalmology, autoimmune, and cardiovascular diseases. 16 October 2018
After already penning two licensing deals in the past few months, HiFiBiO Therapeutics has today announced the acquisition of H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics. 16 October 2018
Roche might be facing increased competition to its well-established breast cancer drug Herceptin (trastuzumab), but the Swiss pharma giant is not sitting still as biosimilars start to take market share. 16 October 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024